We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Rtw Biotech Opportunities Ltd | RTW | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.51 | 08:25:12 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.51 |
| Top Posts |
|---|
Posted at 03/10/2024 15:40 by rambutan2 Also had an IPO and another new investment over the last couple of weeks: |
Posted at 03/10/2024 15:38 by rambutan2 Their play on a huge, albeit currently very competitive, mkt:Roderick Wong, Managing Partner and CIO at the Investment Manager commented on the launch, "We are immensely proud to co-lead the Series A launch of Kailera Therapeutics, our fourth new company creation at RTW. Kailera represents a significant step forward in addressing the huge market for chronic weight management and metabolic diseases. With its clinically-validated pipeline and experienced management team, we are confident that Kailera is well-positioned to develop breakthrough therapies that will profoundly improve the lives of patients worldwide. We look forward to supporting them on this transformative journey." |
Posted at 15/9/2024 22:00 by rambutan2 Interim report, released on fri, is a good read, with some interesting portfolio details: |
Posted at 16/7/2024 19:45 by rambutan2 End of quarter update etc. Still on sale on a 20% discount and in a still beaten down sector... |
Posted at 11/6/2024 11:06 by affemoose Investment Subsid' sale - $4.5m for RTWhxxps://www.marketsc |
Posted at 23/3/2024 20:39 by rambutan2 Apogee (APGE) is another big, up 50%, riser this month on the back of trial news and subsequent raise. RTW was a backer from pre IPO at multiples lower. |
Posted at 21/3/2024 22:09 by rambutan2 Yes, very wrongly priced currently. The sector trades on around a 10% discount, so this has got really out of wack. And especially so considering it is a top performer and has a quality manager. It offers a rare opportunity to buy a real no brainer. imho.Sector stats: I note that in the last fact sheet, Avidity came from nowhere to be 9% of nav. Since then, it is up approx 40% on good news and a fund raise in which RTW participated. This just illustrates one of the great advantages offered by being part of the RTW platform, one of the elite bio investors in the States. |
Posted at 21/2/2024 19:10 by rimau1 Its a good question, not really small single digit accretive was it!! They have set out all the reasons why a downward revision could have occurred since 31 Jan. Most likely is that they have now applied the RTW valuation methodology to the Arix privately held assets. I also think the the Jan 31 NAV of $1.94 was artificially high since it included the 25.5% stake in Axis that they had purchased for £1.37 which was worth £1.44 at 31 Jan. Just a guess. |
Posted at 21/2/2024 15:10 by jaf111 Agree that it certainly looks attractive but have to admit being very disappointed with the $1.88 proforma number.When the “merger” was announced last November RTW stated it was expected to be immediately accretive to RTW NAV per share…… But the end Jan (pre merger) NAV was $1.94 per share……. Have I missed something?????? |
Posted at 14/2/2024 08:19 by rimau1 Of course there are Weatherman, its much more complicated than that as you know. Quality of management team, composition of holdings, sector, exit opportunities/realis |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
